China’s regulatory agency has agreed to consider a request that pamiparib, BeiGene‘s investigational PARP inhibitor, be approved to treat people with advanced ovarian cancers after at least two prior lines of chemotherapy. The company’s new drug application (NDA), submitted to the Center for Drug Evaluation of the Chinese National Medical Products Administration, is specifically for patients with ovarian, fallopian tube, or primary peritoneal cancer whose tumors have, or are thought to have, mutations in BRCA, a DNA…
You must be logged in to read/download the full post.
The post PARP Inhibitor Pamiparib Under Review in China to Treat Advanced Ovarian Cancer appeared first on BioNewsFeeds.